Noble Financial Weighs in on MariMed FY2026 Earnings

MariMed Inc. (OTCMKTS:MRMD) – Equities research analysts at Noble Financial issued their FY2026 earnings per share (EPS) estimates for MariMed in a research note issued on Monday, March 16th. Noble Financial analyst J. Gomes anticipates that the company will post earnings of ($0.05) per share for the year.

Separately, Zacks Research upgraded MariMed from a “strong sell” rating to a “hold” rating in a research note on Thursday, January 1st. One equities research analyst has rated the stock with a Strong Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy”.

MariMed Stock Up 3.9%

Shares of OTCMKTS MRMD opened at $0.08 on Wednesday. The business has a 50-day moving average price of $0.09 and a 200 day moving average price of $0.11. The stock has a market cap of $31.02 million, a PE ratio of -2.60 and a beta of 1.11. The company has a quick ratio of 0.38, a current ratio of 1.00 and a debt-to-equity ratio of 1.44. MariMed has a 52-week low of $0.07 and a 52-week high of $0.23.

About MariMed

MariMed Inc is a multi‐state cannabis company focused on the development, ownership and operation of regulated facilities for the medical and adult‐use cannabis markets. Headquartered in New Bedford, Massachusetts, the company cultivates, processes and dispenses cannabis through an integrated business model that encompasses cultivation, formulation, manufacturing and retail operations. MariMed operates under its own licensed brands and through strategic partnerships to expand its presence across the United States.

The company’s product portfolio includes branded flower, pre‐rolls, vaporizer cartridges, tinctures, edibles and topicals designed to meet a range of consumer and patient needs.